RIGL
Rigel Pharmaceuticals IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$536.75M
P/E Ratio
1.50
EPS
$19.29
Beta
1.20
52W High
$52.24
52W Low
$18.14
50-Day MA
$28.65
200-Day MA
$34.70
Dividend Yield
—
Profit Margin
121.50%
Forward P/E
6.44
PEG Ratio
-0.10
About Rigel Pharmaceuticals Inc
Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat blood disorders, cancer, and rare immune diseases. The company is headquartered in South San Francisco, California.
Fundamentals
| Revenue (TTM) | $299.77M |
| Gross Profit (TTM) | $243.41M |
| EBITDA | $126.99M |
| Operating Margin | 20.20% |
| Return on Equity | 174.10% |
| Return on Assets | 22.90% |
| Revenue/Share (TTM) | $16.53 |
| Book Value | $21.64 |
| Price-to-Book | 1.34 |
| Price-to-Sales (TTM) | 1.79 |
| EV/Revenue | 1.453 |
| EV/EBITDA | 3.32 |
| Quarterly Earnings Growth (YoY) | -30.20% |
| Quarterly Revenue Growth (YoY) | 10.30% |
| Shares Outstanding | $18.50M |
| Float | $15.95M |
| % Insiders | 3.28% |
| % Institutions | 94.26% |
Historical Volatility
HV 10-Day
91.66%
HV 20-Day
72.04%
HV 30-Day
63.68%
HV 60-Day
57.67%
HV Rank
63.5%
Volatility is currently expanding
Analyst Ratings
Consensus ($53.20 target)
3
Buy2
HoldMore HEALTHCARE Stocks
Data last updated: 5/25/2026